 SALT LAKE CITY, July 22, 2021 PRNewswire -- Co-Diagnostics, Inc. Nasdaq: CODX, a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Koreas Intellectual Property Office for the Companys CoPrimerTM technology. Developed in 2013, Co-Diagnostics solely-owned CoPrimer technology received its first patent from the United States Patent Office in 2018, and underpins the Companys molecular diagnostic test products that have been deployed in laboratories and hospitals in over 50 countries and across the United States. 